Skip to content
View rushadnihal's full-sized avatar
  • Joined Oct 30, 2026

Block or report rushadnihal

Block user

Prevent this user from interacting with your repositories and sending you notifications. Learn more about blocking users.

You must be logged in to block users.

Content in all repositories owned by your account will be closed.
Maximum 250 characters. Please don’t include any personal information such as legal names or email addresses. This note will only be visible to you.
Report abuse

Contact GitHub support about this user’s behavior. Learn more about reporting abuse.

Report abuse
rushadnihal/README.md

Hi, I'm Rushad Nihal

Biostatistician with an M.S. in Biostatistics (Arizona State University, GPA 3.97) and a B.Tech in Biotechnology. I work on clinical-trial statistics: designing trials, writing and following statistical analysis plans, fitting the models regulators expect (MMRM, Cox, logistic), and checking results in both SAS and R.


Across the clinical trial lifecycle

Stage What I've built Project
Design Sample size, Lan-DeMets group-sequential boundaries, Bayesian go/no-go interims; every number validated against rpact and gsDesign trialdesign
SAP and estimands SAP frozen under a git tag before any outcome was seen; ICH E9(R1) estimand; MMRM with missing-data sensitivity analyses oasis2-mmrm-trial-simulation
CDISC deliverables SDTM → ADaM → TLFs in SAS, with derived datasets checked against the published PHUSE ADaM files (PROC COMPARE) cdisc-pilot-sas-adam-tlf
Independent validation Primary MMRM fitted in R (mmrm) and SAS (PROC MIXED, DDFM=KR); estimates and SEs agree within 1e-6 oasis2-mmrm-trial-simulation
Evidence synthesis / HTA Random-effects meta-analysis and meta-regression with heterogeneity, publication-bias and leave-one-out checks bcg-vaccine-trials
Real-world evidence Target trial emulation with inverse-probability weighting and survival outcomes causal-survival-analysis

Featured projects

oasis2-mmrm-trial-simulation: MMRM, estimands and trial simulation · R, SAS

Trial-style longitudinal analysis of brain-volume decline in OASIS-2.

  • SAP v1.0 frozen before outcomes, with every later change logged as a deviation
  • MMRM primary analysis, robustness checks (covariance, time model, visit windows) and MNAR delta-adjustment and reference-based imputation (rbmi)
  • SAS/R double programming that agrees to 1e-6
  • ADEMP simulation study (888,000 simulated trials) of type I error, power and sample size: 64 per arm for 80% power, 86 allowing for 30% dropout
  • Quarto report, renv-pinned, CI runs the full pipeline on synthetic data

trialdesign: clinical trial design package · Python

CLI and API for designing two-arm trials before the data exist.

  • Fixed designs for continuous, binary and time-to-event endpoints
  • Group-sequential designs (O'Brien-Fleming / Pocock spending, non-binding futility) solved by recursive numerical integration
  • Bayesian beta-binomial interim with predictive probability of success and assurance
  • Exact operating characteristics checked against 200,000-trial simulations; validated against rpact, gsDesign and base R in CI
  • Includes a design memo written the way I'd present a design to a clinical team

cdisc-pilot-sas-adam-tlf: CDISC SDTM → ADaM → TLF · SAS

Submission-style programming on the public CDISC pilot study (xanomeline vs placebo, 254 randomized): ADSL, ADAE and ADTTE derived from SDTM with dataset specs; disposition, baseline, exposure and adverse-event tables; Kaplan-Meier/Cox with a proportional-hazards check; ANCOVA and a repeated-measures model for ADAS-Cog. Derived datasets are reconciled against the published PHUSE ADaM files with PROC COMPARE, and outputs go to RTF/PDF with saved logs and a validation checklist.

bcg-vaccine-trials: meta-analysis for evidence synthesis · R

Random-effects meta-analysis of 13 BCG vaccine trials (metafor): pooled RR 0.49 (95% CI 0.34–0.70), I² = 92%, and a latitude meta-regression that explains 76% of the heterogeneity. Includes Knapp-Hartung and permutation tests, six τ² estimators, Egger/Begg tests, trim-and-fill and leave-one-out analyses. These are the methods used in HTA submissions (e.g. IQWiG/AMNOG, NCPE).

aact-trial-outcomes-sql-sas: clinical trial registry analysis · SQL, SAS

What predicts early termination and late or missing results reporting in 44k Phase 2/3 drug trials on ClinicalTrials.gov: PostgreSQL cohort build, then SAS logistic and Cox models with sponsor-clustered standard errors.

causal-survival-analysis: target trial emulation · Python

ACEi/ARB use and cardiovascular death in type 2 diabetes with CKD (NHANES 2005–2018, n = 2,540). Covariate balance after weighting is good (largest SMD 0.051) but the estimate is inconclusive. The repo explains why (residual healthy-user bias, sample size) and validates the methods on simulations with a known truth.


More work

Project What it is Stack
multi-omics-biomarker-pipeline Leakage-controlled clinical + 5-gene survival signature for lung adenocarcinoma (TCGA-LUAD), frozen and validated on two external cohorts (Harrell C 0.715 and 0.697) Python
myco-rsm Response surface / design-of-experiments media optimizer for fermentation R, Shiny
adni-subgroup-calibration-code In progress: calibration audit of MCI-to-dementia risk models across landmark times and demographic subgroups in ADNI (code only; data cannot be redistributed) R

Toolbox

Languages: SAS, R, Python, SQL SAS: PROC MIXED, PHREG, LIFETEST, LOGISTIC, SURVEYLOGISTIC, FREQ, MEANS, REPORT, COMPARE, SQL, macros, ODS RTF output R: mmrm, emmeans, nlme, lme4, survival, rbmi, mice, metafor, rpact, gsDesign, tidyverse, Shiny, Quarto Python: numpy, scipy, pandas, statsmodels, lifelines, scikit-survival, scikit-learn Clinical standards: CDISC SDTM and ADaM, ICH E9 and E9(R1) estimands, SAP writing, double programming / QC Methods: group-sequential and Bayesian trial design, mixed models for repeated measures, survival analysis, missing data (MAR/MNAR, reference-based imputation), causal inference, meta-analysis, simulation studies (ADEMP) Reproducibility: Git, GitHub Actions CI, renv, pytest, synthetic-data pipelines for confidential data

Background

  • M.S. Biostatistics, Arizona State University (2025, GPA 3.97/4.00)
  • B.Tech Biotechnology, Manipal Institute of Technology (2023)
  • Data Science Analyst, ASU × Global Observatory for Physical Activity (GoPA!): built a country-year panel for six African countries, compared naive-drift, ETS and ARIMA forecasts to 2030, and screened predictors with PCA and lagged cross-correlation (confidential data, not shared)
  • iGEM, Manipal team: Bronze (2021) and Gold (2022)
  • Lab background in microbiology, molecular biology, PCR and bioprocess QC, so I can talk to the scientists whose data I analyse

Currently

Writing up the ADNI calibration audit and learning German (A1).

Get in touch

Email is the best way to reach me: rushadisatwork@gmail.com

Pinned Loading

  1. oasis2-mmrm-trial-simulation oasis2-mmrm-trial-simulation Public

    MMRM natural-history analysis of OASIS-2 brain volume, SAS/R cross-check, and trial simulation study.

    R

  2. aact-trial-outcomes-sql-sas aact-trial-outcomes-sql-sas Public

    Reproducible SQL + SAS analysis of ClinicalTrials.gov (AACT, 2026-11-15 snapshot): what predicts early termination and late or missing results reporting in 44k interventional Phase 2/3 drug trials.…

    SAS 1

  3. cdisc-pilot-sas-adam-tlf cdisc-pilot-sas-adam-tlf Public

    SDTM to ADaM to TLFs in SAS for the public CDISC pilot study (CDISCPilot01): ADSL/ADAE/ADTTE derivation, QC against PHUSE ADaM with PROC COMPARE, tables, Kaplan-Meier and Cox, and a PROC MIXED repe…

    Rich Text Format 1

  4. ADNI-Subgroup-Calibration-code ADNI-Subgroup-Calibration-code Public

    R code for a landmark audit of MCI-to-dementia risk prediction in ADNI: calibration by landmark time, protocol era and demographic subgroup. Working draft; ADNI data not included.

    R 1

  5. causal-survival-analysis causal-survival-analysis Public

    Target trial emulation of ACEi/ARB and cardiovascular mortality in type 2 diabetes with CKD (NHANES + NCHS linked mortality)

    Python 1

  6. multi-omics-biomarker-pipeline multi-omics-biomarker-pipeline Public

    Leakage-controlled multi-omics survival biomarker pipeline for TCGA-LUAD with frozen signature and external validation

    Python 1